LENSAR (NASDAQ:LNSR) Issues Earnings Results, Misses Estimates By $0.02 EPS

LENSAR (NASDAQ:LNSR) issued its quarterly earnings data on Tuesday. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02), FiscalAI reports. The company had revenue of $16.03 million during the quarter, compared to the consensus estimate of $20.30 million.

Here are the key takeaways from LENSAR’s conference call:

• The planned acquisition by Alcon was mutually terminated after FTC opposition; LENSAR regained the $10 million escrow deposit and will continue as an independent company.
• Management says the ALLY Robotic Cataract Laser was validated by the acquisition interest and achieved ~200 installed systems (up ~48% year-over-year) and U.S. market share growth to 23.4%, supporting competitive strength.
• Recurring procedure revenue strengthened—2025 recurring revenue rose ~15% to $46.3 million (Q4 annualized >$50M) and comprised ~79% of Q4 revenue, providing higher-margin, predictable cash flow.
• International distributor uncertainty tied to the acquisition caused a meaningful slowdown in outside‑U.S. system sales (only one OUS sale in Q4), and management expects several quarters to rebuild OUS momentum.
• Despite ~$17.1M of merger-related charges and Q4 revenue of $16 million (down 4% YoY), LENSAR reported positive adjusted EBITDA for 2025, forecasts 46–49% gross margin in 2026, and expects ≤10% growth in cash-based operating expenses as it reactivates commercial efforts.

LENSAR Stock Performance

NASDAQ:LNSR opened at $5.97 on Thursday. The stock has a market capitalization of $71.31 million, a P/E ratio of -2.06 and a beta of 0.99. The company has a 50 day moving average price of $10.57 and a 200 day moving average price of $11.23. LENSAR has a fifty-two week low of $5.35 and a fifty-two week high of $14.31.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in shares of LENSAR by 129.0% during the third quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock worth $25,000 after buying an additional 1,131 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of LENSAR by 584.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company’s stock valued at $62,000 after buying an additional 3,991 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in LENSAR during the 2nd quarter worth about $68,000. New York State Common Retirement Fund acquired a new position in LENSAR during the 2nd quarter worth about $105,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in LENSAR during the 3rd quarter valued at about $125,000. 40.15% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LNSR has been the topic of several recent analyst reports. Lake Street Capital raised LENSAR from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Wednesday. BTIG Research raised LENSAR from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Tuesday, March 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of LENSAR in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.